Forte Biosciences (FBRX) Return on Capital Employed (2017 - 2026)

Forte Biosciences (FBRX) has 10 years of Return on Capital Employed data on file, last reported at 149.89% in Q1 2026.

• On a quarterly basis, Return on Capital Employed fell 5111.0% year-over-year to 149.89% in Q1 2026; TTM through Mar 2026 was 149.89%, a 5111.0% decrease from a year earlier, with the FY2025 full-year figure at 137.41%, down 4855.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 149.89%, down from 102.13% in the prior quarter.
• Over the last five years, Return on Capital Employed for FBRX reached as high as 30.54% in Q3 2022 and fell as low as 265.28% in Q3 2024.
• Historically, Return on Capital Employed has averaged 95.38% across 5 years, with a median of 87.72% in 2023.
• Across the five-year window, Return on Capital Employed plunged 16845 bps in 2024 and soared 20553 bps in 2025, its largest moves.
• Year by year, Return on Capital Employed stood at 34.41% in 2022, then sank by 137 bps to 81.7% in 2023, then sank by 46 bps to 119.33% in 2024, then climbed by 14 bps to 102.13% in 2025, then slumped by 47 bps to 149.89% in 2026.
• Per Business Quant data, the three most recent Return on Capital Employed figures were 149.89% in Q1 2026, 102.13% in Q4 2025, and 59.74% in Q3 2025.